Stay updated on Nivolumab+Vorolanib Safety/Activity in Thoracic Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+Vorolanib Safety/Activity in Thoracic Tumors Clinical Trial page.

Latest updates to the Nivolumab+Vorolanib Safety/Activity in Thoracic Tumors Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe ClinicalTrials.gov record for the nivolumab–vorolanib study in refractory thoracic tumors is displayed, including study details and results information. The record indicates that the study is completed and is no longer recruiting participants.SummaryDifference73%

- Check20 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2. The page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedA site-wide banner announces an NIH website transition and says some content may use “Super Intelligence” instead of “Artificial Intelligence.”SummaryDifference1%

- Check34 days agoChange DetectedThe footer’s site revision label changes from v3.7.1 to v3.7.2, while the page continues to display a 403 error.SummaryDifference0.2%

- Check41 days agoChange DetectedThe site footer revision identifier changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study details, and the rendered content includes standard error page elements (doctype, meta, header, footer) rather than the study information and documents that were previously displayed.SummaryDifference22%

Stay in the know with updates to Nivolumab+Vorolanib Safety/Activity in Thoracic Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+Vorolanib Safety/Activity in Thoracic Tumors Clinical Trial page.